Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment

Trial Profile

Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Ixazomib (Primary) ; Dexamethasone
  • Indications Multiple myeloma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 13 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 14 Apr 2016 Planned End Date changed from 1 Nov 2015 to 1 Jun 2016.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top